Renalytix Plc (FRA:2O9)

Market Cap	11.85M -66.6%
Revenue (ttm)	2.81M +35.1%
Net Income	-16.95M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0245
Previous Close	0.0250
Day's Range	0.0245 - 0.0250
52-Week Range	0.0225 - 0.1260
Beta	n/a
RSI	22.41
Earnings Date	Apr 1, 2026

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl...

• Industry: Prepackaged Software
• Founded: 2018
• Employees: 46
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2O9

Financial Performance

In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.

Financial numbers in USD